Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [911]

ASCO GU 2019: Updates on treatment and management of bladder cancer

Professor Matthew Galsky, Professor Ananya Choudhury, Professor Joaquim...

ASCO GU 2019: Updates on treatment and management of bladder cancer ( Professor Matthew Galsky, Professor Ananya Choudhury, Professor Joaquim Bellmunt, Dr Andrea Necchi )

ASCO GU 2019 renal highlights

Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA

ASCO GU 2019 renal highlights ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )

BGICC 2019 ( )

Combined ibrutinib and venetoclax in patients with treatment-naïve high-risk CLL

Dr Nitin Jain - MD Anderson Cancer Centre, Houston, USA

Combined ibrutinib and venetoclax in patients with treatment-naïve high-risk CLL ( Dr Nitin Jain - MD Anderson Cancer Centre, Houston, USA )

Phase II trial of nivolumab combined with ibrutinib for patients with Richter...

Dr Nitin Jain - MD Anderson Cancer Centre, Houston, USA

Phase II trial of nivolumab combined with ibrutinib for patients with Richter transformation ( Dr Nitin Jain - MD Anderson Cancer Centre, Houston, USA )

Blinatumomab as second salvage therapy in adults with relapsed/refractory...

Prof Alessandro Rambaldi - University of Milan, Milan, Italy

$Blinatumomab as second salvage therapy in adults with relapsed/refractory aggressive B-NHL ( Prof Alessandro Rambaldi - University of Milan, Milan, Italy )$

Cytotoxic T lymphocyte cell therapy for post-transplant lymphoproliferative...

Prof Mohamad Mohty - Saint-Antoine Hospital, Paris, France

Cytotoxic T lymphocyte cell therapy for post-transplant lymphoproliferative disorder in the central nervous system ( Prof Mohamad Mohty - Saint-Antoine Hospital, Paris, France )

Gilteritinib combined with induction and consolidation chemotherapy in newly...

Dr Keith Pratz - Johns Hopkins University, Baltimore, USA

Gilteritinib combined with induction and consolidation chemotherapy in newly diagnosed AML patients ( Dr Keith Pratz - Johns Hopkins University, Baltimore, USA )

Matched targeted therapy for paediatric patients with relapsed, refractory or...

Dr Yana Pikman - Dana Farber Cancer Institute, Boston, USA

$Matched targeted therapy for paediatric patients with relapsed, refractory or high-risk leukemias ( Dr Yana Pikman - Dana Farber Cancer Institute, Boston, USA )$

ECHELON-2: Study into brentuximab vedotin and CHP versus CHOP in the frontline...

Dr Lorenz Trümper - Georg August University, Göttingen, Germany

ECHELON-2: Study into brentuximab vedotin and CHP versus CHOP in the frontline treatment of patients with T-Cell lymphomas ( Dr Lorenz Trümper - Georg August University, Göttingen, Germany )

KRd versus VRd in patients with newly diagnosed multiple myeloma

Dr Ola Landgren - Memorial Sloan Kettering Cancer Centre, New York, USA

KRd versus VRd in patients with newly diagnosed multiple myeloma ( Dr Ola Landgren - Memorial Sloan Kettering Cancer Centre, New York, USA )

Landscape change with oral proteasome maintenance in multiple myeloma patients

Prof Maria-Victoria Mateos, Prof Wee Joo Chng, Prof Meral Beksac and Dr Sagar...

Landscape change with oral proteasome maintenance in multiple myeloma patients ( Prof Maria-Victoria Mateos, Prof Wee Joo Chng, Prof Meral Beksac and Dr Sagar Lonial )

More from ecancer